MK-2206 2HCl

Catalog No.S1078

MK-2206 2HCl Chemical Structure

Molecular Weight(MW): 480.39

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

Size Price Stock Quantity  
In DMSO USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 370 In stock
USD 570 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 183 Publications

21 Customer Reviews

  • Inhibition of AKT signaling abolishes MKK4 phosphorylation on Ser78 in injured axons. Cultures of sensory neurons were treated with 5 µM MK-2206 or 5 µM GDC-0068 for 1 hr prior to axotomy. Axonal proteins harvested at indicated time points after axotomy were subjected to immunoblot analysis.

    Cell, 2015, 160(1-2): 161-76 . MK-2206 2HCl purchased from Selleck.

    j,k, Gene expression ofMYOCD (j) and ACTA2 ( SMA, k) after applying inhibitors of key components involved in the DDR2 downstream signalling pathway to HSCs cultured within 3D collagen matrix subjected to stretching (ST) (n=3, one-way ANOVA, **P=0.0036, ****P<0.0001). l,m, Expression of SMA was significantly reduced after treatment with related inhibitors in early-stage FμNs. (n=4, one-way ANOVA, ***P=0.001, ****P<0.0001). AKT-i: MK-2206

    Nature Materials, 2017, 16:1252-1261.. MK-2206 2HCl purchased from Selleck.

  • The PI3K or AKT inhibition does not restore sensitivity to WZ4002 in PC9 WZR. PC9GR4 or WZR10 cells were treated with WZ4002 alone at the indicated concentrations or in combination with the AKT inhibitor MK-2206 (1 uM). MK-2206 effectively inhibited AKT in both cells.

    Cancer Discov 2012 2, 934-47. MK-2206 2HCl purchased from Selleck.

    Cancer Cell 2013 24, 766-76. MK-2206 2HCl purchased from Selleck.

  • VE-cadherin-induced Akt activation mediates YAP phosphorylation and translocation in ECs. HUVECs were starved for 1h and treated with thrombin (1U) for 1h. Total cell lysates were probed with anti-pAkt, Akt or b-actin antibody. The representative blots of three independent experiments are depicted, and the normalized values for p-Akt are shown. HUVECs were cultured and starved as described as in d and incubated for 8h in complete medium with the Akt inhibitor, MK-2206 (1 uM). pAkt, Akt, pYAP and YAP were detected by western blotting using specific antibodies.

    Nat Commun 2015 6:6943. MK-2206 2HCl purchased from Selleck.

    Rap1b negatively regulates neutrophil transcellular migration by limiting PI3K-Akt signaling. (A-D) Effect of Akt inhibitor MK2206 (2 uM), Src inhibitor PP2 (10 uM), or vehicle control (DMSO) on WT or Rap1b-/- neutrophil functions. (A) Percentage of neutrophil transendothelial migration in 3D migration model. (B) ECM degradation assessed on Oregon green-labeled gelatin matrix; (left) representative images on (bar, 10 um) and (right) bar graph is percentage of matrix degradation. (C) Percentage of cells forming multiple protrusions. (D) Percentage of neutrophils present at junction of activated bEND.3 in 3D migration assay. Mean ?SD; n = 3 independent experiments. **, P < 0.01; ***, P < 0.001; NS, not significant using unpaired Student's t test).

    J Exp Med 2014 211(9), 1741-58. MK-2206 2HCl purchased from Selleck.

  • Inhibitors of AKT or ERK overcome SDF-1a-mediated resistance to ibrutinib-triggered PARP and caspase 3 cleavage in CXCR4S338X-expressing BCWM.1 cells. CXCR4S338X-expressing WM cells were treated with ibrutinib (0.5 uM) alone or in the presence of SDF-1a (20 nM) and/or the AKT inhibitors MK-2206 (0.5 uM) and AZD-5363 (0.5 uM); or the MEK inhibitors AS-703026 (0.25 uM), AZD-6244 (0.5 uM) and UO126 (5.0 uM). (a) Immunoblotting results for phosphoAKT (S473) and phospho-ERK (T202/Y204) in CXCR4S338X-expressing BCWM.1 cells pretreated with ibrutinib with and without AKT or ERK inhibitors, then subjected to SDF-1a stimulation for 2 min. The inhibitory effect of AZD-5363 on AKT, which is known to paradoxically hyper-phosphorylate pAKT(S473) was confirmed by inhibition of the phospho-activity for the downstream AKT targets glycogen synthase kinase 3b and pS6. (b) Immunoblotting results for cleaved PARP and cleaved caspase 3 in CXCR4S338X-expressing BCWM.1 cells treated with ibrutinib and/or AKT or ERK inhibitors for 6 h at IC50 doses. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.

    Leukemia 2015 29(1), 169-76. MK-2206 2HCl purchased from Selleck.

    Induction of apoptosis positively correlates with FOXO3a protein levels and phosphorylation. (a) Treatment of 11 cell lines seeded in 6-well plates with 8 μM MK-2206 or DMSO for 48 hours. Nuclei were harvested for PI staining and FACS analysis and the differences between drug and no drug are displayed as in Figure b. Both conditions were performed in triplo for each cell line. Below the FACS data is a we stern blot of cell lysates from this panel treated with 8 μM MK-2206 or DMSO and harvested at 24 hours. Each cell line name corresponds to the two western lanes below it and the four cell cycle bars above it.

    Cancer Res 2013 73, 2189-98. MK-2206 2HCl purchased from Selleck.

  • Mean IL-8 concentrations determined by ELISA of the supernatants of HeLa cells infected with wild-type Salmonella. Kinase inhibitors are indicated on the x axis, and the target families of the inhibitors are indicated above each column. CEC, chelerythrine; Pim Inh, Pim-1 inhibitor 2. Inhibitors that significantly affected IL-8 production relative to the control (P < 0.05, Bonferroni post hoc test from one-way ANOVA) are indicated with an asterisk. Relative cell viability is also shown, as determined by reduction of XTT by viable cells. A450, absorbance at 450 nm.

    Sci Signal 2011 4, rs9. MK-2206 2HCl purchased from Selleck.

    Reducing cellular levels of PtdIns5P by overexpression of PIP4Kα inhibits clonogenic growth of U2OS but enhances cell survival in response to H2O2 stimulation. A) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), PI-103 (0.5 μM), U0126 (5 μM), or SB203580 (5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown. B) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), MK-2206 (1 μM), triciribine (1 μM), KU0063794 (1 μM), or PI-103 (0.5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown.

    FASEB J 2013 27, 1644-56. MK-2206 2HCl purchased from Selleck.

  • A. Western blot analysis of pAKT activation in ovarian cancer cell lines treated with exogenous IGF-1. B. Activation of pAKT by IGF-1 in low-grade ovarian cancer cell lines was blocked by the AKT inhibitor MK-2206 in a dose-dependent manner.

    Gynecol Oncol 2011 123, 13-8. MK-2206 2HCl purchased from Selleck.

    Comparative effects of inhibitors by immunofluorescence microscopy study. Confluent HC11 cells were grown on poly-L-lysine-coated glass coverslips (immunofluorescence) and on plastic plates (biochemical control) and then treated with inhibitors according to the standard procedure. Upper part: the biochemical action of the inhibitors was tested to validate the immunofluorescence results. Cellular proteins were analyzed by SDS-PAGE and the immunoblots were successively probed with anti-ADRP, anti-β-casein, and anti- β-actin antibodies and their respective HRP-conjugated secondary antibodies. Each experimental condition was performed in duplicate. Lower part: cells were fixed, permeabilized and subjected to immunofluorescence microscopy using antiserum against ADRP and TRITC-conjugated secondary antibody (red).

    Biochim Biophys Acta 2012 1823, 987-96. MK-2206 2HCl purchased from Selleck.

  • Confocal microscopy images of NO formation. DAF 2 DA-loaded washed platelets (1.0109 platelets/mL) were preincubated at 378C with saline (A), and then stimulated for 1min with 0.1 (B), 1.0 (C) or 10 (D) μM AEA. In Panel (E-F-G) washed platelets were preincubated with 1 μM SR1 (E), 1 Mm MK2206 (F) or 20 μM LY294002 (G), and then stimulated for 1min with 1.0 μM AEA. In panel (H) is reported the effect of 5 mg/mL collagen, used as a positive control. All the experiments were carried out in the presence of 100 μM L-arginine. NO formation was visualized by confocal microscropy as detailed in Methods.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

    The AEA effect on eNOS phosphorylation. Washed platelets (1.0109 platelets/mL), preincubated at 378C with saline, 1 μM SR1, 1 μM SR2, 20 μM LY294002, 1 μM MK2206, 1.0 μM EGTA, or 30 μM BAPTA/AM, were stimulated for 1 min with 1.0 μM AEA. At the end of incubation suitable aliquots were immunoblotted with anti-p-eNOSser1177 as detailed in Methods.Blots are representative of five independent experiments.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

  • Effect of selected agents on NOx and cGMP formation induced by AEA. Washed platelets (1.0109 platelets/mL), prewarmed at 378C with saline or 1mM SR1, 1 μM SR2, 20 μM URB597 (URB), 1 μM MK2206 (MK) or 20 μM LY294002 (LY), were incubated for 1min with 100 μM L-arginine in the presence of 1.0 μM AEA. NOx (panel A) and cGMP (panel B) content were determined as detailed in Methods. Each bar represents the meanSD of five independent experiments carried out in triplicate. Student,s t-test: P <0.0001 versus none;P <0.0005; P <0.005 versus AEA

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

    C.U87MG cells were treated with vehicle or 1 μM MK-2206 for 1 hr, and then irradiated with 6 Gy. Total cell lysate was harvested 1 hr after IR and subjected to Western blot analysis with the indicated antibody. Cells without IR treatment were used as a control.

    D. Cells were treated with vehicle (control) or 1 μM MK-2206 for 1 hr, then irradiated with indicated dosage. 4 hr after IR, cells were fed with drug-free medium, and incubated for another 20 hr at 37°C, after which they were trypsinized and seeded for clonogenic survival assay. Colony-forming efficiency was determined 14 d later.
     

     

    Radiat Oncol 2009 4, 43. MK-2206 2HCl purchased from Selleck.

  • (B) Dose-response curves for DIPG 4 and SF7761 cells treated with the small molecule AKT inhibitor MK-2206 (error bars represent SEM).

    Oncol Rep, 2018, 39(2):455-464. MK-2206 2HCl purchased from Selleck.

    MK-2206 2HCL inhibited the sorafenib-induced PI3K/mTOR pathway activation and enhanced the cytotoxic effects of sorafenib in resistant cell lines. (A) HUH-7 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved PARP were revealed by Western blotting. (B) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved RARP were revealed by Western blotting. (C) HUH-7 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (D) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (*P < 0.05, HUH-7, SK-HEP-1 are control groups, R-HUH-7, R-SK-HEP-1 are resistant groups).

    J Surg Res, 2016, 206(2):371-379. MK-2206 2HCl purchased from Selleck.

  • IC50 values for an Akt inhibitor (MK-2206) and a MEK inhibitor (U0126) in a panel of mouse and human anaplastic (ATC) and follicular (FTC) carcinoma cell lines. On the bottom, a Western blotting showing the effect on the activation of Akt and ERK1/2 of one hour exposure to these inhibitors (MK-2206: 500 nM, U0126: 10 μM).

    Oncotarget 2011 2, 1109-26. MK-2206 2HCl purchased from Selleck.

    After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of MK-2206 for 3h,followed by 15-minute stimolation of 100ng/ml EGF.

     
     

     

    Dr. Zhang of Tianjin Medical University. MK-2206 2HCl purchased from Selleck.

  •  

    PI3K pathway signaling in GDC-0941 and MK-2206 treated MCF-7 derivatives with PIK3CA or  AKT1 mutations. Cells were grown in medium containing 5% FBS and treated with vehicle or increasing concentrations of GDC-0941 (0 nM, 50 nM, 100 nM, and 400 nM) or MK-2206 (0 nM, 100 nM, 250 nM, 1000 nM). After 24 hours of drug treatment, lysates were prepared and equal amounts of protein were load ed onto SDS-PAGE gels and blotted with the indicated antibodies.

    MK-2206 2HCl purchased from Selleck.

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.
Features The first allosteric small molecule inhibitor of Akt to enter clinical development.
Targets
Akt1 [1]
(Cell-free assay)		 Akt2 [1]
(Cell-free assay)		 Akt3 [1]
(Cell-free assay)
8 nM 12 nM 65 nM
In vitro

MK-2206 is an allosteric inhibitor and is activated by the pleckstrin homology domain. MK-2206 inhibits auto-phosphorylation of both Akt T308 and S473. MK-2206 also prevents Akt-mediated phosphorylation of downstream signaling molecules, including TSC2, PRAS40 and ribosomal S6 proteins. [1] MK-2206 inhibits Ras wild-type (WT) cell lines (A431, HCC827, and NCI-H292) more potently when compared to Ras-mutant cell lines (NCI-H358, NCI-H23, NCI-H1299, and Calu-6). MK-2206 also shows synergistic responses in combination with cytotoxic agents such as erlotinib or lapatinib in lung NCI-H460 or ovarian A2780 tumor cells. [2] MK-2206 or siRNA-mediated Akt inhibition strongly activates autophagy in human glioma cells. However, eukaryotic elongation factor-2 (eEF-2) silencing suppresses MK-2206-induced-autophagy, with a promotion of apoptotic cell death. [3]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-H292 MXvDfZRwfG:6aXOgRZN{[Xl? M2f6VFMh|ryP M{ixPVczKGh? NGftblBFVVOR MX\Jcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdg>? Mm\ONlA2PzFyNkm=
A431 MXnLbY5ie2ViQYPzZZk> MnLxOUDPxE1? NXnGOoJVPSCq MVrEUXNQ M2WzUnN2eHC{ZYPz[ZMhfGinIIPp[45idGmwZzDv[kBCc3RiYX7kJGVzcw>? NWj6N4E6OjB3N{GwOlk>
HepG2 NYHzPWhyS3m2b4TvfIlkKEG|c3H5 NG\6N2gyOCEQvF2= M33OOVI1KGh? NIS4VmNFVVOR NYK4TJRwW2Wwc3n0bZpmeyC{ZYPpd5RidnRiY3XscJMhfG9idHjlJIN6fG:2b4jpZ{Bm\m[nY4Sgc4Yhe2:{YX\lcolj MoXCNlEzODV7MkW=
Sk-Hep1 M{nUTWN6fG:2b4jpZ{BCe3OjeR?= NXjYd5dZOTBizszN M4f1d|I1KGh? NF7oXnZFVVOR NHi4enBU\W6|aYTpfoV{KHKnc3nzeIFvfCClZXzsd{B1dyC2aHWgZ5l1d3SxeHnjJIVn\mWldDDv[kB{d3KjZnXubYI> NGHlXlkzOTJyNUmyOS=>
OCUT1 cells harbored PIK3CA (H1047R+/+) NGPx[mFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfid|h2OyEQvF2= M1jBTlUh\A>? MkX2SG1UVw>? MYfJR|UxRTBwMUSg{txO Mn7yNlEzQDl{Nke=
K1 cells harbored PIK3CA (E542K+/+) M2OzRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXGzJO69VQ>? NIP2[3k2KGR? M2TJZ2ROW09? MYrJR|UxRTBwNUKg{txO MnPPNlEzQDl{Nke=
FTC133 cells harbored PTEN (allele deletion and R130+) M2fCSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HibVMh|ryP MlTmOUBl MV7EUXNQ NVzGfGU3UUN3ME2wMlE5KM7:TR?= MoXxNlEzQDl{Nke=
C643 cells harbored HRAS (G13R+/−) NHnwSmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml[zN{DPxE1? NH\xUZg2KGR? NWnwdnhKTE2VTx?= NUHqTGpUUUN3ME2wMlI4KM7:TR?= NV65NYlPOjF{OEmyOlc>
Hth7 cells harbored NRAS (Q61R+/−) M4DZTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjES2E{KM7:TR?= M4X0O|Uh\A>? NHvHbWtFVVOR M4ewUWlEPTB;ND61JO69VQ>? MnTFNlEzQDl{Nke=
TPC1 cells harbored RET/PTC1 rearrangement NGfVOG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjaN{DPxE1? NHHZUo42KGR? NXTmTVlHTE2VTx?= NWPmdm9nUUN3ME2wMlU6KM7:TR?= M{DS[lIyOjh7Mk[3
Hth74 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEe1R5Y{KM7:TR?= MXK1JIQ> Ml3XSG1UVw>? NVTsdpJiUUN3ME2yMlE6KM7:TR?= M2PQfFIyOjh7Mk[3
KAT18 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nQOVMh|ryP M1zTblUh\A>? Mn7jSG1UVw>? MmHKTWM2OD12Lk[yJO69VQ>? MUCyNVI5QTJ4Nx?=
SW1736 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWCxNFAh|ryP MmHrOUBl M3jkU2ROW09? MUnJR|UxRTR5LkW2JO69VQ>? M4jndVIyOjh7Mk[3
WRO MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHUWJdJOTByMDFOwG0> MkfLOUBl M2L5WmROW09? MUnJR|UxRjFyMECg{txO NF7yOHYzOTJ6OUK2Oy=>
TAD2 MkXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU[xNFAxKM7:TR?= NXzuV4JSPSCm NV3pUZA6TE2VTx?= MYnJR|UxRjFyMECg{txO NFuyWWMzOTJ6OUK2Oy=>
LN229 M3joPGFxd3C2b4Ppd{BCe3OjeR?= MUmwMlUh|ryP NX[1fm1NPjBiaB?= MXrEUXNQ MYPBeYdu\W62czDhdI9xfG:pZX7pZ{Bm\m[nY4TzJI9nKGenZnn0bY5q[g>? NEfjW5YzOjB3N{mxOC=>
T98G MWHBdI9xfG:|aYOgRZN{[Xl? NVPpcZE6OC53IN88US=> NHu1PY43OCCq M3f1TmROW09? NWG3cGFVSXWpbXXueJMh[XCxcITv[4VvcWNiZX\m[YN1eyCxZjDn[YZqfGmwaXK= MmLjNlIxPTd7MUS=
HC11 M4W2SmZ2dmO2aX;uJGF{e2G7 M3rr[FExKM7:TR?= M2HQbFI1KGh? MoToSG1UVw>? MnP3TY5pcWKrdIOg{tIu[2G|ZXnuJIFv\CCDRGLQJJN6dnSqZYPpdy=> Mlu3NlI1OjZ4MkG=
MOLT-4 NYnPeIVkS3m2b4TvfIlkKEG|c3H5 MXexNEDPxE1? MUi0PEBp MmT4SG1UVw>? NV:zUIxpUUN3ME2xMlfjiIoQvF2= NE\rcJQzOjZzNEK0Ny=>
CEM-R NXm2bmhzS3m2b4TvfIlkKEG|c3H5 M4C5OFExKM7:TR?= MYm0PEBp NEPTTYNFVVOR MXvJR|UxRTNwM,MAje69VQ>? NY\vfHZ2OjJ4MUSyOFM>
CEM-S NV3KdnJbS3m2b4TvfIlkKEG|c3H5 M3H1[lExKM7:TR?= NFrpV2M1QCCq NEPaPFFFVVOR MlfuTWM2OD13LkJihKnPxE1? NED3boYzOjZzNEK0Ny=>
MOLT-4 NYH2OXpWTnWwY4Tpc44hSXO|YYm= M4XUdVExKM7:TR?= NIXzT3MzPCCq Ml\nSG1UVw>? NVjlR|RYSmyxY3vzJINmdGy|IHnuJJRp\SCJMD;HNUBxcGG|ZTDv[kB1cGViY3XscEBkgWOuZR?= MUiyNlYyPDJ2Mx?=
MOLT-4 MonkSpVv[3Srb36gRZN{[Xl? MWO05qCK|ryP M1LYUVQhcA>? NH;XXWtFVVOR NEPUPGVKdmO{ZXHz[ZMhfGinIHHtc5VvfCCxZjDjcIVifmWmIFzDN2EwSixiYTD3[YxtNWW|dHHicIl{cGWmIHH1eI9xcGGpeTDtZZJs\XJ? MlHhNlI3OTR{NEO=
CEM-R MUfGeY5kfGmxbjDBd5NigQ>? MoP5OQKBkc7:TR?= MkDUOEBp MYPEUXNQ M2SwSmlv[3KnYYPld{B1cGViYX3veY51KG:oIHPs[YF3\WRiTFO0RU9DNCCjIIflcIwu\XO2YXLsbZNp\WRiYYX0c5Bp[We7IH3hdotmeg>? M3;aPVIzPjF2MkSz
CEM-S MmLPSpVv[3Srb36gRZN{[Xl? MUW05qCK|ryP Mn7VOEBp M4XqdWROW09? NEPzb4VKdmO{ZXHz[ZMhfGinIHHtc5VvfCCxZjDjcIVifmWmIFzDOWEwSixiYTD3[YxtNWW|dHHicIl{cGWmIHH1eI9xcGGpeTDtZZJs\XJ? MkDINlI3OTR{NEO=
HepG2 cell NIj6TYxMcW6jc3WgRZN{[Xl? NGS4W2YzOCEQvF2= NWG4dm86OjRiaB?= MVPEUXNQ MWLEc5dvemWpdXzheIV{KHSqZTDwbI9{eGixconsZZRqd25ib3[gRWtV NHLVSFMzOzd7N{OxPS=>
HepG2 cell M3HZVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXiN|Ah|ryP NXvUeYRsOjRiaB?= MmTISG1UVw>? NF7ENFFKdmirYnn0d{Bk\WyuIHfyc5d1cA>? M1\mV|I{Pzl5M{G5
HepG2 cell NG\FZmhCeG:ydH;zbZMhSXO|YYm= MoTZNlAh|ryP NWjmXGNEOjRiaB?= MlrLSG1UVw>? NWS4Z29PUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NFL6S|EzOzd7N{OxPS=>
GEO MnW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoGzOVAxKG6P M1HUNlczKGh? M3vYSmROW09? MVLJcohq[mm2czDj[YxtKGe{b4f0bC=> MViyOFU5OTJ|MR?=
CNE-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fJcFExKM7:TR?= MkPwPVYhcA>? M3SxTGROW09? MUnJR|UxRTJwOU[g{txO MmrXNlU{OzZ7MkW=
CNE-2 M325d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG[z[nUyOCEQvF2= Mom0PVYhcA>? MYTEUXNQ MVnJR|UxRTRwNUOg{txO NYi3N49sOjV|M{[5NlU>
HONE-1 NYDNRWw2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfINVAh|ryP NV25N2luQTZiaB?= NInVR2FFVVOR M4HVR2lEPTB;Mz6zO{DPxE1? M37rfVI2OzN4OUK1
SUNE-1 MlHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLENVAh|ryP M4TmO|k3KGh? MWXEUXNQ NIK0RYtKSzVyPUCuOVIh|ryP NELQdW0zPTN|NkmyOS=>
CNE-2 M3LBV2Z2dmO2aX;uJGF{e2G7 MXSxNEDPxE1? NV\HNGNkPDhiaB?= Mk\QSG1UVw>? NIL1[ZFKdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIF1KEdz MXSyOVM{Pjl{NR?=
HONE-1 MmDtSpVv[3Srb36gRZN{[Xl? MW[xNEDPxE1? NFm0VWo1QCCq NFPnU4NFVVOR MU\JcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHH0JGcy MUWyOVM{Pjl{NR?=
NEC8 NGjKWpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrPeGV4UUN3ME2wMlA6PjVzIN88US=> NIG4eZlUSU6JRWK=
P12-ICHIKAWA NE[wcI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTBwMUG2NkDPxE1? M1HvRnNCVkeHUh?=
MDA-MB-175-VII M2rGR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\MNGlEPTB;MD6xN|c{QCEQvF2= NIjm[HdUSU6JRWK=
AsPC-1 NWXXdFVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MluwTWM2OD1yLkKyNVIzKM7:TR?= M3;3NHNCVkeHUh?=
T47D NF[3W|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjSSVRKSzVyPUCuNlgzPSEQvF2= MXHTRW5ITVJ?
HH Mn;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LSVmlEPTB;MD6zNFI5OyEQvF2= MonrV2FPT0WU
MOLT-16 NYrVPGMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7LTWFKSzVyPUCuN|A{OiEQvF2= NXuyO3dCW0GQR1XS
ES5 NHnue4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTBwM{S0OVUh|ryP MWjTRW5ITVJ?
RS4-11 M2HDNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHacHFKSzVyPUCuN|Q3OSEQvF2= MVnTRW5ITVJ?
KARPAS-45 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTBwM{ezNlEh|ryP NFrOU4JUSU6JRWK=
NCI-H720 MluyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrZWoYyUUN3ME2wMlM4Pjd7IN88US=> MlLzV2FPT0WU
H9 M1H6cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvISHlZUUN3ME2wMlM5QDh|IN88US=> MkDiV2FPT0WU
EFM-19 M3ziUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIGwZVBKSzVyPUCuOFQxOSEQvF2= NF7CU3BUSU6JRWK=
SBC-1 Ml\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfkZYlVUUN3ME2wMlQ1ODN3IN88US=> M4HQfnNCVkeHUh?=
A4-Fuk NYGxeIxwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwNE[4Olgh|ryP MmjoV2FPT0WU
NCI-H1563 NH\1fYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHze4ZEUUN3ME2wMlQ5OTh7IN88US=> NWfQTFJwW0GQR1XS
HCC1419 M{e4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXyTWM2OD1yLkS4PFkzKM7:TR?= MmLSV2FPT0WU
H-EMC-SS MmDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTBwNEm5N|kh|ryP MYTTRW5ITVJ?
BHT-101 Mn;pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXTTWM2OD1yLkWyPVYyKM7:TR?= MkTxV2FPT0WU
IGROV-1 M17uc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTBwNUWyOFkh|ryP NH\j[3FUSU6JRWK=
HGC-27 M4LsRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3X5[GlEPTB;MD61Olc5OyEQvF2= MUnTRW5ITVJ?
MDA-MB-361 NIDXRVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjKeHpKSzVyPUCuOVc4PjFizszN MoH2V2FPT0WU
KE-37 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWK1U|ZnUUN3ME2wMlU5OjZizszN M374RnNCVkeHUh?=
HCC70 NV7kVHZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrjTWM2OD1yLkW5PFI4KM7:TR?= NVLkXlBsW0GQR1XS
LNCaP-Clone-FGC MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;NR3lqUUN3ME2wMlYyODR6IN88US=> NGniR|NUSU6JRWK=
HAL-01 NFLHTJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfGTWM2OD1yLk[yNVMh|ryP NFewXnBUSU6JRWK=
HT M1:xOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrLTWM2OD1yLk[zNlM6KM7:TR?= NVnWbHgzW0GQR1XS
MDA-MB-415 NEPDdI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXUXpd4UUN3ME2wMlY{PjJ4IN88US=> NHm2d5lUSU6JRWK=
NOS-1 MkLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1j6cWlEPTB;MD62N|czOyEQvF2= NWfNRnlsW0GQR1XS
DU-145 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTFTWM2OD1yLk[0O|Q2KM7:TR?= NYfrNG9EW0GQR1XS
OCUB-M Mk\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXRTY5DUUN3ME2wMlcxQTZ4IN88US=> MU\TRW5ITVJ?
VA-ES-BJ NUHXNFVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnERm1KSzVyPUCuO|MxOjVizszN NFPqdVlUSU6JRWK=
J-RT3-T3-5 NEHhTZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXCRZVrUUN3ME2wMlc1PDB|IN88US=> NIThem5USU6JRWK=
MOLT-4 NGjPbndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHPcYZKSzVyPUCuPFA2QDJizszN NITvTZFUSU6JRWK=
NB7 NXPxO2F4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml25TWM2OD1yLkiyOFEyKM7:TR?= NWTu[lRbW0GQR1XS
L-363 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NImzUm5KSzVyPUCuPFM1PDJizszN NFPNXlRUSU6JRWK=
NKM-1 NEK5N41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTBwOE[yOVMh|ryP NFHlcGtUSU6JRWK=
HOP-92 MkPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\zTWM2OD1yLki3NlI{KM7:TR?= MWDTRW5ITVJ?
OAW-42 NUXPUXJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXQRppKSzVyPUCuPFg4OiEQvF2= NUDXUXRLW0GQR1XS
HuO9 NHi4RXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vzd2lEPTB;MD65Nlc2OSEQvF2= NX74eXg5W0GQR1XS
MFE-280 Mke1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIC1[mpKSzVyPUCuPVY1PjVizszN M1f6dHNCVkeHUh?=
EM-2 M{W0cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvaTWM2OD1yLkm3PVM6KM7:TR?= NH6wOmRUSU6JRWK=
NCI-H520 Mm\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLQTWM2OD1yLkm4OVkzKM7:TR?= MljxV2FPT0WU
LB2241-RCC M2fkOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGr6eWdKSzVyPUCuPVk4OzRizszN MoT4V2FPT0WU
SK-NEP-1 NUnRWotXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rGd2lEPTB;MT6xOFQ5PSEQvF2= M4ThdXNCVkeHUh?=
LXF-289 NYXP[HBsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXzb5lKSzVyPUGuNVcyPTZizszN MlLkV2FPT0WU
EPLC-272H NEDxe5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moj0TWM2OD1zLkG3NlU3KM7:TR?= MXnTRW5ITVJ?
COLO-684 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPJTWM2OD1zLkKzO|I2KM7:TR?= MVTTRW5ITVJ?
ES1 MmG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXveo9QUUN3ME2xMlI1ODZ3IN88US=> NUPPcZNKW0GQR1XS
DOHH-2 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXSzZYhmUUN3ME2xMlI5OjB|IN88US=> MljDV2FPT0WU
CTB-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7ldXIxUUN3ME2xMlI5QTlizszN M2DTWXNCVkeHUh?=
G-401 NHXQfGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnKxTWM2OD1zLkK5O|k2KM7:TR?= MVHTRW5ITVJ?
LoVo NWTsdms{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHrTWM2OD1zLkOyOVM1KM7:TR?= NXXUZ4d[W0GQR1XS
Ramos-2G6-4C10 NI\0bXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnITWM2OD1zLkOzO|AyKM7:TR?= NFKyWJpUSU6JRWK=
MFM-223 NW\5RmJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELIU4ZKSzVyPUGuN|Q1PjFizszN MWfTRW5ITVJ?
PA-1 MoX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DnNGlEPTB;MT6zOVI3PSEQvF2= Mk\aV2FPT0WU
697 NIm3W2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\tU5A6UUN3ME2xMlM4PjF4IN88US=> NWPFWZI{W0GQR1XS
QIMR-WIL NH;kO2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkOxTWM2OD1zLkS5NVE3KM7:TR?= MoD1V2FPT0WU
HOS NIO1dGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnsW5pKSzVyPUGuOFk2PThizszN MmD3V2FPT0WU
DMS-273 NIXhUXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXtTWM2OD1zLkWxPVU6KM7:TR?= MnzQV2FPT0WU
ME-180 MnTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTFwNU[4PVEh|ryP MYrTRW5ITVJ?
HCC2218 Ml7MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfkW4JKSzVyPUGuOlgzOjVizszN MYPTRW5ITVJ?
CAL-54 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HCeWlEPTB;MT63NVI1OiEQvF2= NW\4OWZDW0GQR1XS
OMC-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fDVmlEPTB;MT63OFY4PyEQvF2= NWTodVZlW0GQR1XS
COR-L105 Ml7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jCe2lEPTB;MT63PVc{PyEQvF2= M1fUdHNCVkeHUh?=
BV-173 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\GellKSzVyPUGuPFExPzRizszN Mm\SV2FPT0WU
RKO NEnVWYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTFwOEexNFEh|ryP MXHTRW5ITVJ?
SNU-387 NH7Hb25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnSSmlKSzVyPUGuPFg1ODZizszN NV23N2t[W0GQR1XS
SW1088 NHW0[ItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rBVGlEPTB;MT65OFYxPiEQvF2= NVTQNZQ1W0GQR1XS
Hs-578-T MljZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoS1TWM2OD1{LkGxOFM{KM7:TR?= MYjTRW5ITVJ?
OC-314 M3:5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M332XmlEPTB;Mj6xOVA5PiEQvF2= MlnmV2FPT0WU
RMG-I MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF6wZo5KSzVyPUKuNVY{QThizszN MVHTRW5ITVJ?
NCI-H1395 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4D5ZmlEPTB;Mj6xPFA6OSEQvF2= NYrKbWhzW0GQR1XS
GAMG M4f6fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILhO5BKSzVyPUKuNlM5PDVizszN M4riVXNCVkeHUh?=
LB1047-RCC MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTJwMkSzNVch|ryP MlPRV2FPT0WU
MN-60 MlywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHR[W9KSzVyPUKuNlk6OjNizszN NUXNb4JYW0GQR1XS
OAW-28 NWfYSHZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTJwMkm5OVEh|ryP NGDvVVlUSU6JRWK=
NCI-H2228 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;jNWlEPTB;Mj6zNVU2OiEQvF2= NIX0O|hUSU6JRWK=
ABC-1 M1f1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTJwM{OyOVMh|ryP MWHTRW5ITVJ?
LS-513 MkG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTrTWM2OD1{LkOzOFg1KM7:TR?= NIfpVFVUSU6JRWK=
KS-1 NVLKco41T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn2xTWM2OD1{LkO4NVkyKM7:TR?= NUPt[G1uW0GQR1XS
NB69 MkniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrGVpZKSzVyPUKuN|g6QDNizszN MmPvV2FPT0WU
VM-CUB-1 M3f0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3aTWM2OD1{LkO5NFg{KM7:TR?= M1zwcHNCVkeHUh?=
D-423MG Mn\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3u1dGlEPTB;Mj60NVA1PCEQvF2= NF;FZWtUSU6JRWK=
EW-18 MnrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLPe5lsUUN3ME2yMlQyQTN7IN88US=> M3LUdnNCVkeHUh?=
YH-13 M4fCZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\FOndrUUN3ME2yMlQ3OTV|IN88US=> NIXrW4lUSU6JRWK=
T-24 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfmTWM2OD1{LkS3PFgyKM7:TR?= NGHrbXZUSU6JRWK=
ES8 M1;rN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPtTWM2OD1{LkS5Nlg4KM7:TR?= NYjpdlhLW0GQR1XS
ES3 NF\vfXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDqTWM2OD1{LkS5O|U6KM7:TR?= MljVV2FPT0WU
RXF393 NFL6NXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\jelQ1UUN3ME2yMlYxPDh5IN88US=> MnKxV2FPT0WU
RPMI-8226 MlvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37COWlEPTB;Mj62Nlk2OyEQvF2= MXHTRW5ITVJ?
AGS M1XXemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzuTWM2OD1{LkeyNVM4KM7:TR?= MlHYV2FPT0WU
HCC1395 M4HpTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPpXotKSzVyPUKuO|UyQDdizszN NYDvbGljW0GQR1XS
MV-4-11 M1[zU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTJwN{WyOlYh|ryP NWPhXVh[W0GQR1XS
A204 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\aemlEPTB;Mj64N|g4OiEQvF2= Mm\qV2FPT0WU
MCF7 Mnf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXH2cVZYUUN3ME2yMlg3OTF5IN88US=> NWXkOYhPW0GQR1XS
SNU-423 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjmO2pKSzVyPUKuPFkzPDJizszN MkPOV2FPT0WU
NCI-H1048 M2TwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDUN2VkUUN3ME2yMlk3QDZ3IN88US=> M1nQcnNCVkeHUh?=
GR-ST NInQT4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PKWGlEPTB;Mz6wOFYyOSEQvF2= MWrTRW5ITVJ?
EoL-1- MmSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTNwMEewOVgh|ryP NFjndXhUSU6JRWK=
HuH-7 NE\BW5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoL2TWM2OD1|LkC5OFY1KM7:TR?= M{XObnNCVkeHUh?=
OS-RC-2 Mn63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrpeo9kUUN3ME2zMlEyOTlizszN MojtV2FPT0WU
EW-3 NVHa[5ZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHOUnV3UUN3ME2zMlE6PTJ7IN88US=> MVfTRW5ITVJ?
NCI-H747 NVvDXm9JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjDTo9KSzVyPUOuNlA3QTRizszN M3XTWXNCVkeHUh?=
EW-16 MlfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTNwMkG4O|kh|ryP NXHESWVOW0GQR1XS
DOK M3zxe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTNwMkK4OVkh|ryP M4nu[nNCVkeHUh?=
HCC2157 NHHoNGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\hTWM2OD1|LkO4NVc6KM7:TR?= MnfVV2FPT0WU
OVCAR-3 M1jWXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTNwNEC3PFYh|ryP Mnu3V2FPT0WU
NCI-H1623 NUftOINoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mor2TWM2OD1|LkSxNlI1KM7:TR?= MYXTRW5ITVJ?
H4 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4T1dmlEPTB;Mz60OVYzPiEQvF2= NX\5PWFPW0GQR1XS
SW1710 NYr2NWVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfLTWM2OD1|LkS2Olc5KM7:TR?= NFjSZW9USU6JRWK=
RT-112 NHfSVYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTNwNUKzPFgh|ryP NWLOTo9LW0GQR1XS
DMS-114 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfLTWM2OD1|Lk[yNlc5KM7:TR?= MknnV2FPT0WU
AN3-CA NXLwNJZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jCe2lEPTB;Mz62NlQ2PiEQvF2= NGPLN2lUSU6JRWK=
KNS-62 NFXpXY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LJPWlEPTB;Mz62N|M{QCEQvF2= NVm0V45[W0GQR1XS
SJRH30 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFq1e4pKSzVyPUOuOlkyOjJizszN M{SxZnNCVkeHUh?=
G-402 Mn7mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13wPWlEPTB;Mz63NFcyOSEQvF2= NGrWTYpUSU6JRWK=
MHH-PREB-1 M2fpR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTNwN{KwN|gh|ryP MUjTRW5ITVJ?
P30-OHK NVrtWlg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILjWIdKSzVyPUOuPFA6PzZizszN NWXuTGZMW0GQR1XS
RVH-421 Mn2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnKTWM2OD1|LkixO|g5KM7:TR?= NFPGVI1USU6JRWK=
LU-134-A NHXzSWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXW2N5Y5UUN3ME2zMlg5PDJ6IN88US=> NXm0e2tXW0GQR1XS
ECC10 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nw[2lEPTB;Mz65N|YzOiEQvF2= NX72RnZTW0GQR1XS
TGW MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXPTWM2OD12LkCyN|A2KM7:TR?= M37ZbXNCVkeHUh?=
MLMA MorVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTtU|drUUN3ME20MlAzQTZ4IN88US=> NFXXXYhUSU6JRWK=
SCC-25 NHLOSVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\ZOGlEPTB;ND6wOlU3PiEQvF2= NV;RcoQ4W0GQR1XS
TYK-nu MnrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfHTWM2OD12LkC5OVM1KM7:TR?= MYXTRW5ITVJ?
LAMA-84 MmHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1SwXmlEPTB;ND6xOFE6OSEQvF2= MULTRW5ITVJ?
Calu-3 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHJPVFNUUN3ME20MlI1PDF4IN88US=> MWLTRW5ITVJ?
NCI-H460 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;YcG1KSzVyPUSuNlY1PDNizszN NIK5UHlUSU6JRWK=
EGI-1 MneyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofXTWM2OD12LkO3O|c5KM7:TR?= MYTTRW5ITVJ?
NCI-H292 M{e0SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\OfHE1UUN3ME20MlM5OTR4IN88US=> MmHwV2FPT0WU
HCE-T NXnTclRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4ixN2lEPTB;ND60NVU4QSEQvF2= M3f6TnNCVkeHUh?=
EW-11 M3noPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjIVI9KSzVyPUSuOFE5OzhizszN M2qyW3NCVkeHUh?=
ATN-1 NVm2V4hCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTDXo9KSzVyPUSuOFQ{ODRizszN NVPIRlZDW0GQR1XS
NB5 MlHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnpPG81UUN3ME20MlU{Pjl5IN88US=> MknFV2FPT0WU
KLE MoHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljmTWM2OD12LkewNVk5KM7:TR?= M1rHb3NCVkeHUh?=
CAL-39 NXzuSmx3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTRwN{KxOFYh|ryP Mn;yV2FPT0WU
TI-73 M1\vfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTRwOEC2NFkh|ryP NIPtN|NUSU6JRWK=
HO-1-N-1 MmPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHIOYZKSzVyPUSuPVQzKM7:TR?= MUTTRW5ITVJ?
786-0 NVzWcVFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELldmdKSzVyPUSuPVQ3PzNizszN M3zXcHNCVkeHUh?=
SK-N-DZ MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjCZnBKSzVyPUSuPVYyPDJizszN MmnEV2FPT0WU
NCI-H446 M17DS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjPR2hKSzVyPUWuNlAxODlizszN M3\xeHNCVkeHUh?=
ETK-1 M1ThN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLSTWM2OD13LkKxNVY2KM7:TR?= NFPPTXNUSU6JRWK=
BT-20 NGr4R4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPFRZJKSzVyPUWuNlE{PTNizszN MVLTRW5ITVJ?
MEL-HO NYjWNoVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHOTWM2OD13LkO3N|M3KM7:TR?= MlzNV2FPT0WU
CAL-27 NHvTV4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3sXHNKSzVyPUWuOFY{OzlizszN NFnPXJJUSU6JRWK=
SW872 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILlV|BKSzVyPUWuOVk1OjhizszN MoDQV2FPT0WU
RPMI-2650 NF[0Rm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPoVpExUUN3ME21MlY3OTl7IN88US=> NV70WoNbW0GQR1XS
PFSK-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGft[W5KSzVyPUWuO|I4OzJizszN NXfT[Jp5W0GQR1XS
SF295 MljxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzlUpFKSzVyPUWuPFA3OzNizszN NWi3eZBWW0GQR1XS
Becker MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTVwOE[0O|Ih|ryP NGLmVFRUSU6JRWK=
Saos-2 NFrjXG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUn0OndoUUN3ME21Mlg3PTNizszN MWPTRW5ITVJ?
SK-OV-3 NWThVYdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnTTZZKSzVyPUWuPVk5OTZizszN NGe2OlVUSU6JRWK=
VMRC-RCZ MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH21NXBKSzVyPU[uNFg4PzNizszN MXXTRW5ITVJ?
EW-22 MoO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzQTWM2OD14LkG5OlQ6KM7:TR?= M2XHXnNCVkeHUh?=
BT-474 NFXRNnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXL[lRlUUN3ME22MlI{OyEQvF2= NF7MNGhUSU6JRWK=
BFTC-909 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTZwM{CzOFUh|ryP NIWwT|BUSU6JRWK=
NB12 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PFV2lEPTB;Nj6zPVA4OSEQvF2= M4HLOHNCVkeHUh?=
D-263MG MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTZwNEWxOlkh|ryP NYrrTWk6W0GQR1XS
SNB75 M2PCXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjn[5VNUUN3ME22MlYxOTR|IN88US=> MV3TRW5ITVJ?
A704 NY\4NmRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{i1S2lEPTB;Nj62N|A3KM7:TR?= M4TSdHNCVkeHUh?=
NCI-H1693 NYj2Uo52T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLNSXVKSzVyPU[uOlM3ODRizszN MWTTRW5ITVJ?
LN-405 NH\wcVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTZwN{m2O|Ih|ryP MkLsV2FPT0WU
CHL-1 M3TuU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{[wSWlEPTB;Nj64NFA4QSEQvF2= NYDFOHhmW0GQR1XS
A498 M4nF[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTZwOEG5OlEh|ryP M{SxfXNCVkeHUh?=
TE-12 NVzYTI5sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLOZ4JKSzVyPU[uPFM5OTdizszN NEmz[29USU6JRWK=
TE-6 M1;UT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTOTWM2OD14LkmzNFM5KM7:TR?= NHL4VWlUSU6JRWK=
AU565 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzHOGdKSzVyPU[uPVY6PTdizszN NGfuS49USU6JRWK=
RD NVfJNFRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfz[op3UUN3ME22Mlk5Ojh2IN88US=> Mof4V2FPT0WU
SW1463 Mn3US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEP0RZlKSzVyPUeuNVEyPjhizszN MoTEV2FPT0WU
LU-99A NFv4bVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonkTWM2OD15LkG0N|IzKM7:TR?= Ml[4V2FPT0WU
NCI-H28 MkTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPCOYdWUUN3ME23MlI6OjRizszN NFvz[GVUSU6JRWK=
MC-IXC NEXLWoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFm2R2VKSzVyPUeuOFg2PzZizszN NV:2TYNQW0GQR1XS
GP5d NVnCWZlGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTdwNEi3OlQh|ryP MnfRV2FPT0WU
GB-1 MmjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTdwNUS4NFQh|ryP M3[0dXNCVkeHUh?=
CAL-33 NEPWXXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTVcItKSzVyPUeuOlYzOzNizszN NXnETHlYW0GQR1XS
MSTO-211H NVK0ZlU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTdwNkezN|Yh|ryP NYDSUXVDW0GQR1XS
TE-5 NYXZdGNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml:yTWM2OD15Lke5N|M1KM7:TR?= NIi4c2lUSU6JRWK=
D-566MG MmTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvsPXBKSzVyPUiuNFQ1OjlizszN NGTENWhUSU6JRWK=
JVM-3 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTtTWM2OD16LkG1NlY5KM7:TR?= NF\VVlZUSU6JRWK=
T98G M4m5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\rb3A3UUN3ME24MlE5ODZ5IN88US=> M2Hvc3NCVkeHUh?=
HCC1954 NUTaV5JmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRThwNEWxNFQh|ryP Mo\hV2FPT0WU
SF126 M3LoXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3WSG5{UUN3ME24MlQ2QTN4IN88US=> MYrTRW5ITVJ?
LB996-RCC NYnsWWtZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnSb2lKSzVyPUiuOVMzPTdizszN M4\sWnNCVkeHUh?=
SKG-IIIa M33MZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILNWZBKSzVyPUiuOlMxPjlizszN MYDTRW5ITVJ?
NCI-SNU-1 NYHlSYxVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknGTWM2OD16Lk[0OlQ{KM7:TR?= MmnJV2FPT0WU
LB771-HNC NGfRV3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nWbGlEPTB;OD62OFY6PiEQvF2= MkjlV2FPT0WU
SCC-4 MlTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LPVWlEPTB;OD62PFIyQSEQvF2= M1;tWHNCVkeHUh?=
CAMA-1 M4[xcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3POSWlEPTB;OD63O|E1PiEQvF2= MY\TRW5ITVJ?
D-502MG NF;UTZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUKwOWs5UUN3ME24Mlc5PjJ7IN88US=> MoTFV2FPT0WU
ESS-1 NYnHRWFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPwTWM2OD16Lki4O|A1KM7:TR?= MYPTRW5ITVJ?
HEC-1 MnyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXFPGhKSzVyPUiuPFk5PjZizszN MkfQV2FPT0WU
NB10 NWD2N|JNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;je2h3UUN3ME25MlAzOjJ2IN88US=> MnvRV2FPT0WU
8505C NFfndZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHq0cXJKSzVyPUmuNFQzOzJizszN MkTpV2FPT0WU
EFO-27 NEC2UopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPEbZdKSzVyPUmuNVY1OTJizszN NV;WfXBlW0GQR1XS
HN NH;GNpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPzPGk{UUN3ME25MlE3PjJ6IN88US=> NWjoSYZIW0GQR1XS
DSH1 MmHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4m4fGlEPTB;OT6yNFg4KM7:TR?= Mke4V2FPT0WU
NBsusSR M1Szfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1Hle2lEPTB;OT6yO|QxOiEQvF2= M4PHO3NCVkeHUh?=
LS-123 M1r0SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPTTWM2OD17LkOxO|YyKM7:TR?= MYXTRW5ITVJ?
SHP-77 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzTUGYyUUN3ME25MlM6QTN3IN88US=> NY\XbXhRW0GQR1XS
ACN M4Trcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PiUGlEPTB;OT61N|I4PyEQvF2= MV7TRW5ITVJ?
U251 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2X0NmlEPTB;OT62OVU1PCEQvF2= NH61d|NUSU6JRWK=
A431 NVvhSHlKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDndG53UUN3ME25MlgxOjN6IN88US=> NVvoOVJbW0GQR1XS
5637 NXTLSHRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3n4SWlEPTB;OT64OFk5PCEQvF2= NHq0VYpUSU6JRWK=
MDA-MB-157 NWrk[lJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rKWWlEPTB;OT65Nlg4QCEQvF2= MmXyV2FPT0WU
A101D MmntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITmfpNKSzVyPUmuPVk6PzRizszN NI[4c21USU6JRWK=
YKG-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTFyLkKwNFYh|ryP MkO1V2FPT0WU
LAN-6 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPM[oVKSzVyPUGwMlIyPjRizszN MoXTV2FPT0WU
OVCAR-5 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTFyLkK0N|Mh|ryP MoXwV2FPT0WU
A549 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\ITWM2OD1zMD6zPVc{KM7:TR?= NIWwOI5USU6JRWK=
no-11 NGLyN4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTFyLkSzOVMh|ryP NXHqVGdCW0GQR1XS
SF539 NXzTemNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;LfpVnUUN3ME2xNE46ODRzIN88US=> M1HRZXNCVkeHUh?=
A388 NHTMXnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzSTWM2OD1zMT6zPFk4KM7:TR?= MYjTRW5ITVJ?
DEL NWC4Z3hKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPu[nJKSzVyPUGxMlQzPCEQvF2= NULlZY06W0GQR1XS
SW954 NH;ZbYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTFzLkS2Olgh|ryP NWPqPWpXW0GQR1XS
TK10 NVvFPIV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTFzLkWyO|Eh|ryP NITJ[41USU6JRWK=
SW756 M3rFR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PtPGlEPTB;MUGuOVI6PCEQvF2= M323THNCVkeHUh?=
PC-3 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TzPGlEPTB;MUGuOVc3PCEQvF2= MUHTRW5ITVJ?
ONS-76 M1\mfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPVZ|hKSzVyPUGxMlY{PiEQvF2= MUPTRW5ITVJ?
A427 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTFzLkewPVMh|ryP NVfKNVBQW0GQR1XS
MEG-01 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PrSmlEPTB;MUGuO|UxQSEQvF2= MXrTRW5ITVJ?
BB30-HNC M1WwbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEH6N4xKSzVyPUGxMlc6QDJizszN NHP4doNUSU6JRWK=
NCI-H1299 NVjaW4E{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHsZ4xKSzVyPUGxMlgxQTNizszN M4TvbnNCVkeHUh?=
GCT NFzkRVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHKS2NKSzVyPUGxMlgzOjhizszN MX\TRW5ITVJ?
D-247MG NHLVb3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3nTWM2OD1zMT65OlY{KM7:TR?= MlvsV2FPT0WU
CFPAC-1 NEPtfYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PNNWlEPTB;MUGuPVc5OiEQvF2= NWnPVY9CW0GQR1XS
EKVX NHXuXpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTF{LkCzNVMh|ryP M1T5fXNCVkeHUh?=
CAL-51 M3jnU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkCwTWM2OD1zMj6wO|E3KM7:TR?= NWW1Xo5bW0GQR1XS
BB49-HNC MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLleFhXUUN3ME2xNk4yOTd5IN88US=> MVnTRW5ITVJ?
RPMI-7951 NYO2SZpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTF{LkG4OVQh|ryP NHn2TY1USU6JRWK=
RH-1 Mnf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPwTWM2OD1zMj6yNVg1KM7:TR?= M3;EZnNCVkeHUh?=
BCPAP MnPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvUPVdwUUN3ME2xNk41PzR7IN88US=> M4f1eHNCVkeHUh?=
GCIY M37sRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTF{LkWyNFkh|ryP MVfTRW5ITVJ?
KNS-81-FD M3\aSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml[yTWM2OD1zMj61PFY6KM7:TR?= M4rRWnNCVkeHUh?=
KYSE-140 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTF{Lki1PVUh|ryP NGr1bFNUSU6JRWK=
Ca-Ski M4fDT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\Wc25tUUN3ME2xNk46ODRzIN88US=> NIDRZnlUSU6JRWK=
TGBC1TKB NV7QTmVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmX3TWM2OD1zMj65NVE2KM7:TR?= MY\TRW5ITVJ?
HCC1187 M3X3PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHyweZlKSzVyPUGzMlE6OTJizszN NEL2[oNUSU6JRWK=
SJSA-1 M4THNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTF|LkKzNlch|ryP NVSwZ|FLW0GQR1XS
CTV-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnziTWM2OD1zMz6zOFUh|ryP NX;tWmxpW0GQR1XS
WM-115 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;3PGlEPTB;MUOuOlQ5OyEQvF2= MWfTRW5ITVJ?
CHP-212 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzSUGhKSzVyPUGzMlk4OzlizszN Mn7GV2FPT0WU
SCC-15 NU\XWpNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTF|Lkm3O|Uh|ryP NHu1RXhUSU6JRWK=
BPH-1 M3vkTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1ezNmlEPTB;MUSuNVY3PCEQvF2= NEHzOItUSU6JRWK=
SW780 MkHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTF2LkWwNlUh|ryP NUi2[XZuW0GQR1XS
NCI-H2291 MmK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWH0UId6UUN3ME2xOE42QDd6IN88US=> MkSzV2FPT0WU
JEG-3 NF7HbnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPiTWM2OD1zND62N|I3KM7:TR?= M2DJTnNCVkeHUh?=
CAL-120 M3z2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPXTWM2OD1zND63NFI4KM7:TR?= MkLGV2FPT0WU
NCI-H23 NHTGOlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTF2Lke5PVch|ryP M1zE[nNCVkeHUh?=
MS-1 NHO3bZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3O3bWlEPTB;MUSuPVYyOSEQvF2= MmPqV2FPT0WU
PC-14 MlLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLyOWpiUUN3ME2xOE46PjV2IN88US=> M{P1XHNCVkeHUh?=
D-283MED MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPuOIJKSzVyPUG1MlAyOTFizszN MmTMV2FPT0WU
OE19 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTF3LkG1OFEh|ryP NHXvTmFUSU6JRWK=
CAS-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfFTXVEUUN3ME2xOU41OTh2IN88US=> NYLsfndLW0GQR1XS
NCI-H727 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTJTWM2OD1zNT60NlIyKM7:TR?= MYDTRW5ITVJ?
SiHa MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rXRWlEPTB;MUWuO|U6PCEQvF2= M{PkWHNCVkeHUh?=
BFTC-905 NVrhd3gyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{j0S2lEPTB;MUWuO|Y6PCEQvF2= MmDOV2FPT0WU
MDA-MB-453 NXj1NIZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYX3TZRCUUN3ME2xOk4yPjR{IN88US=> MnnHV2FPT0WU
HuP-T3 NV2weI11T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3tTWM2OD1zNj62N|c{KM7:TR?= M2nIZXNCVkeHUh?=
SK-LU-1 M1rzNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWi3emJxUUN3ME2xOk43QTV4IN88US=> NUnsfFZIW0GQR1XS
Detroit562 M170VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHIRWtKSzVyPUG2Mlc{OThizszN MYTTRW5ITVJ?
HCC1569 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTF4LkizN|ch|ryP MVHTRW5ITVJ?
SK-MES-1 NWTueHdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3tfXRCUUN3ME2xOk45PDF7IN88US=> MUHTRW5ITVJ?
BB65-RCC M{fpWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHLbW9KSzVyPUG3MlA1PzlizszN M2f1enNCVkeHUh?=
LOXIMVI NH7IcmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX6wbWRUUUN3ME2xO{4xPzB5IN88US=> NYPuUmd1W0GQR1XS
SW1783 M{LsT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjnSHdKSzVyPUG3MlEzQCEQvF2= MmDvV2FPT0WU
NH-12 NGn5[41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTF5LkOzNFMh|ryP MoThV2FPT0WU
UACC-257 MoLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LJRWlEPTB;MUeuOVUyOiEQvF2= M1HBcHNCVkeHUh?=
KOSC-2 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPLTWM2OD1zNz62O|U4KM7:TR?= NVXq[4xOW0GQR1XS
KG-1 M3\OcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHX2bJdKSzVyPUG3MlY6OzdizszN NUnnN2U4W0GQR1XS
M059J MlvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;R[WlEPTB;MUeuO|A{KM7:TR?= NH7hVFFUSU6JRWK=
MHH-NB-11 MoTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTF5Lkm2O|Mh|ryP NEPqO2NUSU6JRWK=
EW-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLaVZBKSzVyPUG4MlE{QDJizszN NVLxRm5XW0GQR1XS
CAL-85-1 NWfnPIw{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXXdoNRUUN3ME2xPE4zOzV5IN88US=> MYjTRW5ITVJ?
639-V Mnu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTF6LkOzOVQh|ryP NHvI[lJUSU6JRWK=
C32 NVW1dopNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\oTWM2OD1zOD60O|I4KM7:TR?= MWXTRW5ITVJ?
KM-H2 M2fNXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TKTmlEPTB;MUiuOVI{OiEQvF2= M1\FbXNCVkeHUh?=
A253 MonxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXzNJhKSzVyPUG4MlczQDZizszN MX\TRW5ITVJ?
NCI-N87 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfEOnpPUUN3ME2xPE46ODB6IN88US=> MlTFV2FPT0WU
8-MG-BA M3S3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1yzfWlEPTB;MUmuNFY1PiEQvF2= NE\jZ3JUSU6JRWK=
GI-ME-N M2Gwcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PRcWlEPTB;MUmuNVU1PiEQvF2= M{D1dXNCVkeHUh?=
8305C MofWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXQTWM2OD1zOT6yNlg3KM7:TR?= M4HZfHNCVkeHUh?=
TE-8 M3r6VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHETWM2OD1zOT6zNFI1KM7:TR?= M{fw[HNCVkeHUh?=
KYSE-270 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHxTWFqUUN3ME2yNE4xOjF5IN88US=> Mli5V2FPT0WU
HL-60 NYrHZYx5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;UOFFKSzVyPUKwMlA6PDFizszN M{PHUXNCVkeHUh?=
Mo-T MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PM[2lEPTB;MkCuNVY3PSEQvF2= MmS1V2FPT0WU
NCI-H1355 M3OwNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYS4OmR{UUN3ME2yNE4{Ozd2IN88US=> MlO2V2FPT0WU
HT-1080 M{nYOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfiOoFKSzVyPUKwMlU1QTdizszN NWXpZVJoW0GQR1XS
MIA-PaCa-2 NUfIRVk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHUTWM2OD1{MD62PFg{KM7:TR?= NEjDOoNUSU6JRWK=
NCI-H441 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEO1UI5KSzVyPUKwMlc{PzlizszN MUfTRW5ITVJ?
LCLC-97TM1 Mn\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXhTWM2OD1{MD64NVM1KM7:TR?= NELEXJZUSU6JRWK=
HT-3 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPSSGVKSzVyPUKxMlU3OzFizszN NEDjXJJUSU6JRWK=
22RV1 NG\iSmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXf3N5BqUUN3ME2yNU42Pjh3IN88US=> NWnSdWxbW0GQR1XS
LK-2 NVz2WpV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjSfYtKSzVyPUKxMlU6PTNizszN NVfyU|dDW0GQR1XS
CW-2 MlTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmCyTWM2OD1{MT62NFY6KM7:TR?= MonmV2FPT0WU
KYSE-510 NH[yfIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4qxd2lEPTB;MkGuOlA6PSEQvF2= M33nXnNCVkeHUh?=
CGTH-W-1 NGe4[HZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTJzLkexOlYh|ryP M3rBVXNCVkeHUh?=
NCI-H661 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7DTJRIUUN3ME2yNk4xOzRizszN NHnJ[IlUSU6JRWK=
KU-19-19 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3MZ4dKSzVyPUKyMlE3QTdizszN NVmxS4RxW0GQR1XS
NCI-H2122 NHq1TGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVf1dGJyUUN3ME2yNk4zPDN{IN88US=> M{[2RnNCVkeHUh?=
NCI-H526 NUnpR4JxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjZ[G5KSzVyPUKyMlM5QTVizszN M4\uSXNCVkeHUh?=
NCI-H1650 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzHblZvUUN3ME2yNk44PjRizszN Ml\zV2FPT0WU
AM-38 M4LNTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHPTWM2OD1{Mj64Olg6KM7:TR?= NVj1bYRPW0GQR1XS
NCI-H2405 M{\jO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXL2fFRUUUN3ME2yN{4zPTN|IN88US=> M{TXXXNCVkeHUh?=
M14 M1;IVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M363PGlEPTB;MkOuOFA5QCEQvF2= MW\TRW5ITVJ?
ES4 NXLW[JJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\QUGFKSzVyPUKzMlQzOzJizszN NUi4PJA4W0GQR1XS
DJM-1 MmSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPyTWM2OD1{Mz61NlM1KM7:TR?= NX\KeZNSW0GQR1XS
S-117 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrkeXpKSzVyPUKzMlc3PTFizszN NXKxTmg4W0GQR1XS
MZ2-MEL NEW4SIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXyS4hKSzVyPUKzMlc4PTlizszN MYDTRW5ITVJ?
SK-MEL-2 NVLvSHZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jPUmlEPTB;MkOuPFE{OyEQvF2= NXfVOolyW0GQR1XS
HCC1806 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTJ|Lki3NFkh|ryP MmPIV2FPT0WU
NMC-G1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTJ2LkKyNlYh|ryP NHnUdpVUSU6JRWK=
DK-MG NYHzUJl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DFR2lEPTB;MkSuNlk1KM7:TR?= MWfTRW5ITVJ?
SK-N-FI NXTCO5dQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofoTWM2OD1{ND6zN|AzKM7:TR?= NUm4U4ZVW0GQR1XS
KINGS-1 NYi5fo1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTJ2LkS4O|Qh|ryP M2\NWnNCVkeHUh?=
HCC2998 NYTWbI1[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2X0dWlEPTB;MkSuOFg5PSEQvF2= NXTD[otOW0GQR1XS
ALL-PO M2fFXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFmyWXVKSzVyPUK0MlYyQSEQvF2= MV7TRW5ITVJ?
MPP-89 M2DQNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3P0eWlEPTB;MkWuNFQ2QCEQvF2= M3;kWXNCVkeHUh?=
NCI-H2342 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrRbGVKSzVyPUK1MlE6PTNizszN NIjJPI5USU6JRWK=
TE-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3i2Z2lEPTB;MkWuN|U3OyEQvF2= NH7CUI5USU6JRWK=
RH-18 MlLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LPbmlEPTB;MkWuOVkyQCEQvF2= NHmxc5dUSU6JRWK=
HT-1376 NU\DW2lxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHGNFRzUUN3ME2yOU43PDZ3IN88US=> MoHlV2FPT0WU
U-2-OS MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7HWJlKSzVyPUK1MlY5QDhizszN MoLlV2FPT0WU
BT-549 MoCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVL4eGpZUUN3ME2yOU46ODFzIN88US=> M3jSOHNCVkeHUh?=
NCI-H1755 NYq2W3N4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3YdI9kUUN3ME2yOU46QTR3IN88US=> NFT1R5ZUSU6JRWK=
EW-13 MnnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHLUIVSUUN3ME2yOk4xOjd2IN88US=> M2PLNXNCVkeHUh?=
NB13 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHaTWM2OD1{Nj6wPVQ6KM7:TR?= M4izRnNCVkeHUh?=
NUGC-3 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTlWo9pUUN3ME2yOk4zOTB|IN88US=> MmLSV2FPT0WU
GMS-10 M2fYNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fwRmlEPTB;Mk[uNlM2OyEQvF2= MkLFV2FPT0WU
CHP-134 M3fZWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDTRYFjUUN3ME2yOk4{QDZ5IN88US=> NGXqbZFUSU6JRWK=
SW962 NWH2c5BtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzxcm1KSzVyPUK2MlUxOjFizszN NY\6[HptW0GQR1XS
SNU-449 NGr3VpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkX0TWM2OD1{Nz6wPFA{KM7:TR?= M3vGZXNCVkeHUh?=
HuP-T4 M37mS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfMTWM2OD1{Nz6wPFc6KM7:TR?= MV7TRW5ITVJ?
SW948 NGjwO3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\0TWM2OD1{Nz6xN|Q1KM7:TR?= NWT0b|lWW0GQR1XS
NCI-H226 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moj6TWM2OD1{Nz60OVc5KM7:TR?= MnvTV2FPT0WU
SK-PN-DW MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTUVVZKSzVyPUK3MlYxOTJizszN MYjTRW5ITVJ?
GI-1 M1\6RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTJ5LkeyNUDPxE1? MVjTRW5ITVJ?
CAL-12T MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTJ6LkGxNVIh|ryP MkHIV2FPT0WU
YAPC MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\uSmlEPTB;MkiuNlU3PCEQvF2= MkfkV2FPT0WU
SNU-C2B NHSxZ5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\2OGdKSzVyPUK4MlI6PjRizszN MX7TRW5ITVJ?
RCC10RGB MkPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1O4eWlEPTB;MkiuOVQyPyEQvF2= NGXyfXBUSU6JRWK=
ES7 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPYfFBKSzVyPUK5MlE1PjVizszN NFTXUXlUSU6JRWK=
PANC-03-27 NVHJdnFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnoTWM2OD1{OT60OFQh|ryP M370Z3NCVkeHUh?=
ES6 NHTUVXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPhdJFKSzVyPUK5MlgyPTdizszN MmHQV2FPT0WU
HT-1197 M1r3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;EcphMUUN3ME2zNE4xPTl6IN88US=> Ml:4V2FPT0WU
ZR-75-30 NIe2[GlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\EVGpVUUN3ME2zNE4zOzh|IN88US=> NYHIWYgzW0GQR1XS
DB NVjIcoN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1u2cWlEPTB;M{CuOFk1OiEQvF2= NWHoNYNTW0GQR1XS
OCI-AML2 MnT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3NXol4UUN3ME2zNU4xPjlizszN Mn7mV2FPT0WU
NCI-H2170 NX6xTI94T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTNzLki1NVYh|ryP NFvUenFUSU6JRWK=
IST-MES1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfJfZVKSzVyPUOyMlI5QTdizszN NX\FbnBzW0GQR1XS
769-P MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTN{LkO2OFEh|ryP MmPVV2FPT0WU
COR-L23 NFHYfWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Xz[WlEPTB;M{KuPVA4OyEQvF2= NEC2c5NUSU6JRWK=
SW626 NXLhe4dIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHZVXBiUUN3ME2zN{4yPzd4IN88US=> M3jQUXNCVkeHUh?=
LU-139 NU\1fWQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTN|Lk[2NFUh|ryP NV7sVG1vW0GQR1XS
HT-144 NULpVVRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTN|Lki2N{DPxE1? MnjCV2FPT0WU
CaR-1 M{PsVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvDU2hyUUN3ME2zN{46QDJ{IN88US=> Mm\jV2FPT0WU
OE33 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrpTWM2OD1|ND6yPFU2KM7:TR?= NXvyW3RLW0GQR1XS
COLO-800 M4nGZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPUflk{UUN3ME2zOE4{PjR5IN88US=> MnvGV2FPT0WU
NB14 NWDxTGhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{m2[GlEPTB;M{SuOFY5PCEQvF2= MojBV2FPT0WU
KURAMOCHI M4TYbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvLSlJKSzVyPUO2MlEyQThizszN NEXxe49USU6JRWK=
SW48 Mlm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTvTWM2OD1|Nj6yOFc1KM7:TR?= M3\kNnNCVkeHUh?=
Daoy NX3hOYhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFi0c3RKSzVyPUO2MlY2OzhizszN MorhV2FPT0WU
TGBC24TKB NFy2Z|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrKTWM2OD1|Nj62O{DPxE1? MmfKV2FPT0WU
DU-4475 M4rpUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITae3NKSzVyPUO2MlkxOzNizszN MUXTRW5ITVJ?
SW1417 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEL3b4tKSzVyPUO4MlA2PTJizszN M1fvenNCVkeHUh?=
EFO-21 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvTN5RmUUN3ME2zPE46OzR7IN88US=> MUnTRW5ITVJ?
MG-63 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvrSoZKSzVyPUO5MlM1OjRizszN NH[xRppUSU6JRWK=
LC-2-ad MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXi1Z2kzUUN3ME2zPU42PTF{IN88US=> NH;3cnBUSU6JRWK=
NOMO-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnOS2VKSzVyPUO5MlgzPzRizszN MVjTRW5ITVJ?
COLO-741 NIjreIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVi0O2JSUUN3ME20NE4yOzB2IN88US=> MlGxV2FPT0WU
BxPC-3 NVniOWp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MneyTWM2OD12MD61Olg3KM7:TR?= NILVUJNUSU6JRWK=
HSC-2 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3:wT2lEPTB;NECuPVEyOyEQvF2= NXP5SoN7W0GQR1XS
UMC-11 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rrdGlEPTB;NEGuNlY{KM7:TR?= MWDTRW5ITVJ?
HCC1937 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PxTmlEPTB;NEKuO|g1OyEQvF2= MYDTRW5ITVJ?
Calu-6 M1KxZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnBPZZIUUN3ME20N{4zOzh{IN88US=> MnnDV2FPT0WU
NCI-H1573 Mn7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzlWnlKSzVyPUSzMlM1PzdizszN MVzTRW5ITVJ?
SK-N-AS MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTR|Lk[wNVkh|ryP M4L0[3NCVkeHUh?=
PSN1 M4jrR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2CzUGlEPTB;NEWuNlU1QCEQvF2= MUfTRW5ITVJ?
TE-11 NESwOHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHK3[lBKSzVyPUS1MlQ5PDJizszN NYHoPJY5W0GQR1XS
NCI-H1155 NVjLN|VLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLQTWM2OD12NT64PVY4KM7:TR?= NUPKdoRNW0GQR1XS
KM12 NXPqPIVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvwTWM2OD12NT65NFc3KM7:TR?= MX;TRW5ITVJ?
RO82-W-1 MoPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjBXGtKSzVyPUS2Mlk5OjJizszN M{fRZ3NCVkeHUh?=
SW1573 MoLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTR5LkO3N|Yh|ryP MmPZV2FPT0WU
CAKI-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnu4TWM2OD12OD6yPFQ2KM7:TR?= MVTTRW5ITVJ?
U-118-MG MnzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTR6LkO3NFIh|ryP NX3OOph3W0GQR1XS
KYSE-520 NGftR5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHe3R|JKSzVyPUS4MlQxOTZizszN NETN[29USU6JRWK=
HT55 M3nDUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljVTWM2OD12OT6xOFc1KM7:TR?= NFftZ2xUSU6JRWK=
ChaGo-K-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXpTWM2OD12OT60O|k{KM7:TR?= NX;BeZkzW0GQR1XS
IA-LM MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTV2Lk[zNlIh|ryP NGjlOI9USU6JRWK=
UACC-62 NFzZTXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrLcmljUUN3ME21OU4yODR4IN88US=> MUHTRW5ITVJ?
MKN7 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWmzNIFIUUN3ME21Ok4xOjh3IN88US=> M17vU3NCVkeHUh?=
HPAF-II NWnZbmVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\BbmlEPTB;NU[uOFA4OyEQvF2= M1nVRXNCVkeHUh?=
NTERA-S-cl-D1 MnrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPwWpdzUUN3ME21O{44PzhizszN NVX2Z4h2W0GQR1XS
FTC-133 M{XocWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHtTWM2OD13OD6wPVY6KM7:TR?= MVTTRW5ITVJ?
MHH-ES-1 NGnjN5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTjcYVVUUN3ME21PE41QDF2IN88US=> NIXXOG9USU6JRWK=
JVM-2 MoXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF6wdoRKSzVyPUW4Mlk2ODZizszN NH;NTIFUSU6JRWK=
TCCSUP M2XKcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTmO4VzUUN3ME21PU42Ojd7IN88US=> M4n3ZXNCVkeHUh?=
COLO-824 NESx[IFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfo[opKSzVyPU[wMlA4OTlizszN NHL2[IJUSU6JRWK=
647-V M2PUSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnKZZNSUUN3ME22NE4yOzR5IN88US=> MnTPV2FPT0WU
HD-MY-Z MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\LTWM2OD14MD61Nlk1KM7:TR?= MlHOV2FPT0WU
LS-411N MmTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTZzLkO5NFMh|ryP MmfjV2FPT0WU
NCI-H596 MoLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHKXpNCUUN3ME22Nk44PDl4IN88US=> MXPTRW5ITVJ?
C-33-A M2S4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrWb5FKUUN3ME22OE4xQTV5IN88US=> NHzpSIxUSU6JRWK=
BHY NIfkVo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYSyN3dQUUN3ME22OE4yOjR3IN88US=> NUjhZ21IW0GQR1XS
KGN NFPC[lFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTZ2LkW1NVQh|ryP MWPTRW5ITVJ?
NCI-H1092 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLjOXBKSzVyPU[1MlAxQTVizszN MUXTRW5ITVJ?
MZ1-PC MnfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXETWM2OD14NT61OlQ6KM7:TR?= NILM[WhUSU6JRWK=
LB831-BLC MmTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVyzXGRrUUN3ME22OU45PDhzIN88US=> MXnTRW5ITVJ?
SW620 MlP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDz[|RyUUN3ME22Ok4zODN7IN88US=> MYnTRW5ITVJ?
HuO-3N1 MoPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TTU2lEPTB;NkiuN|I{QCEQvF2= NHvP[mlUSU6JRWK=
SK-HEP-1 M{jIbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnETWM2OD14OT65OFg3KM7:TR?= NXzZSJVwW0GQR1XS
LCLC-103H MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojHTWM2OD15MD62O|A2KM7:TR?= MUTTRW5ITVJ?
KYSE-70 NYrDXpY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nOeGlEPTB;N{CuO|g{PSEQvF2= M1HpPXNCVkeHUh?=
Mewo M4XKNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnMXIJKSzVyPUexMlUxPSEQvF2= NYHPfWFOW0GQR1XS
COLO-668 NHmxZWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGri[FJKSzVyPUexMlg1PTFizszN M2LL[HNCVkeHUh?=
NCI-H522 NGrPWVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jDPGlEPTB;N{KuN|QyOyEQvF2= NHnicotUSU6JRWK=
NCI-H1437 M4PZZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjGeWNbUUN3ME23OE41ODR6IN88US=> MWjTRW5ITVJ?
U-266 NWX0cWZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnT4TWM2OD15NT60OVE3KM7:TR?= NGDRUpRUSU6JRWK=
MC116 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TM[mlEPTB;N{WuOVcxQCEQvF2= MYPTRW5ITVJ?
PANC-10-05 M1;oSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\0e3NKSzVyPUe3MlQzPDNizszN NU\lcZNbW0GQR1XS
KYSE-180 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVGwXGlXUUN3ME23O{42PDV2IN88US=> M1rOb3NCVkeHUh?=
JAR NY\5UI9XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnsc2V4UUN3ME23PU4xPTR4IN88US=> NUL0Uo5NW0GQR1XS
CAL-62 NF3TTVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\tTWM2OD16MD6wPVUh|ryP M{[0V3NCVkeHUh?=
A3-KAW MnvDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRThyLkKxOVQh|ryP NI\IeZRUSU6JRWK=
PANC-08-13 M1XUO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPwPZlKSzVyPUixMlE4PjhizszN NYTzU2RFW0GQR1XS
HSC-3 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nid2lEPTB;OEOuN|A4OSEQvF2= NYPr[JRGW0GQR1XS
HTC-C3 M4rndWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7vTWM2OD16Mz60O|AzKM7:TR?= M{iyT3NCVkeHUh?=
KY821 M2niUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M130XmlEPTB;OESuNFg6OiEQvF2= NGXvVVVUSU6JRWK=
DoTc2-4510 NUTPb5huT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorPTWM2OD16ND6yNVg2KM7:TR?= NYDLUVdWW0GQR1XS
NCI-H1581 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX63eVNRUUN3ME24OU41PjRzIN88US=> NInuTZFUSU6JRWK=
KARPAS-299 NXO1bFNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;GR5BKSzVyPUi2MlE6PzdizszN NEDuOo5USU6JRWK=
IST-MEL1 NELpNHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTh4Lki4O|Ih|ryP MmCzV2FPT0WU
KP-N-YS M3LybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPQTpN{UUN3ME24PU46ODJ6IN88US=> MY\TRW5ITVJ?
KYSE-410 MlTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjmb5NKUUN3ME25NU41ODR{IN88US=> NIPOfJZUSU6JRWK=
TE-10 M4PIT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTlzLkW2NVEh|ryP M2LuNXNCVkeHUh?=
SK-MEL-1 M1j4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{D3TGlEPTB;OUKuPVExPiEQvF2= MoGyV2FPT0WU
COLO-792 MlzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnmTWM2OD17NT6yOVY1KM7:TR?= MnHZV2FPT0WU
SCH NXLYXZJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEW4fYJKSzVyPUm2MlM5PzdizszN MljPV2FPT0WU
NCI-H1792 NUXWR4hzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrxTWM2OD17Nj64PVkzKM7:TR?= Ml\aV2FPT0WU
NCI-H2029 MkLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVWwepVIUUN3ME25Ok46PTZ4IN88US=> MkXJV2FPT0WU
SW684 M4ruR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTl6Lk[2OVQh|ryP MYPTRW5ITVJ?
NCI-H209 NIDLbpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7RTWM2OD1zMECuNVIyKM7:TR?= M{K0NnNCVkeHUh?=
HLE M1PLVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17PT2lEPTB;MUC1MlI5OiEQvF2= NYLnNZFCW0GQR1XS
GOTO M3TSb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTFyNz63O|ch|ryP MUfTRW5ITVJ?
NCI-H1793 NV;BV4F4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfaTWM2OD1zMEmuNlgh|ryP Mmr3V2FPT0WU
D-392MG MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFG3VZVKSzVyPUGxO{4{QThizszN MYrTRW5ITVJ?
SW1990 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUG4XolKUUN3ME2xNlAvQTVzIN88US=> NVv4Vlg4W0GQR1XS
ML-2 M2HieWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3iwPWlEPTB;MUKxMlY4PiEQvF2= MYrTRW5ITVJ?
NCI-H2452 NFvI[2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTF{Mj6yNUDPxE1? MVfTRW5ITVJ?
SK-MEL-30 NIjue5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTF{Mz6yOFQh|ryP M2ThT3NCVkeHUh?=
SN12C MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTF{ND6xO|Yh|ryP MWfTRW5ITVJ?
NCI-H1770 M1\D[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvrTWM2OD1zMkWuOVE1KM7:TR?= NIT6UIpUSU6JRWK=
SF268 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTF{Nj6xOVgh|ryP M3K3VHNCVkeHUh?=
BALL-1 Mn;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzJeYlKSzVyPUGyOk4zOyEQvF2= MXLTRW5ITVJ?
COLO-679 M1rpO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvvTWM2OD1zMk[uO|U{KM7:TR?= MWPTRW5ITVJ?
A2780 NInIOY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoSzTWM2OD1zMkiuPVg5KM7:TR?= NWn1U|NXW0GQR1XS
NCI-H1651 NH7ZWnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTF|MT6yOFMh|ryP NH20emlUSU6JRWK=
NCI-H2087 NWC5[XppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnSbmdKSzVyPUGzNU41QDNizszN NWG4PG9RW0GQR1XS
U-87-MG MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlu5TWM2OD1zM{OuOlA1KM7:TR?= MWTTRW5ITVJ?
LB2518-MEL NXHCeJgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1y1OmlEPTB;MUO1Mlk6OyEQvF2= NVHDU3M3W0GQR1XS
HCT-116 NUfRSlZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLyTWM2OD1zM{euNlE4KM7:TR?= NIjmcnNUSU6JRWK=
Ca9-22 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILLfZBKSzVyPUGzPU45OzNizszN MXrTRW5ITVJ?
COR-L88 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTF2Mj6xOEDPxE1? Mn24V2FPT0WU
CP50-MEL-B MmT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVH2dYEzUUN3ME2xOFQvPTBzIN88US=> NGSxUXpUSU6JRWK=
OVCAR-8 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVv3R|VuUUN3ME2xOFUvPjN4IN88US=> M3HI[nNCVkeHUh?=
SK-MEL-3 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3xflRHUUN3ME2xOFcvQDd6IN88US=> MUXTRW5ITVJ?
GT3TKB MnmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;lcoJKSzVyPUG0PU46OjhizszN M2\2ZnNCVkeHUh?=
KYSE-450 MnTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIO5S4RKSzVyPUG1NU42OzlizszN NWDxT2lyW0GQR1XS
CAPAN-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTF3Mz6wOlQh|ryP NFexWZVUSU6JRWK=
BEN MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHSNVU5UUN3ME2xOVMvQTJ6IN88US=> M3:3VXNCVkeHUh?=
NCI-H1304 MmrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTDWYpUUUN3ME2xOVQvPjl2IN88US=> NI\McIxUSU6JRWK=
KU812 NWnLeYVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HBUGlEPTB;MUW4MlY4PCEQvF2= M4rzd3NCVkeHUh?=
Capan-2 NVHPUm5nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzGbnZKSzVyPUG2NE42PTNizszN NH3hRVdUSU6JRWK=
A673 M3zDT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHRTmtKSzVyPUG2NU44ODVizszN MX;TRW5ITVJ?
SAS NIexeY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jrXWlEPTB;MU[yMlY4QCEQvF2= MXzTRW5ITVJ?
NY MmTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVv0WYttUUN3ME2xOlUvOzF2IN88US=> NIi4WnVUSU6JRWK=
HCE-4 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTGcZA2UUN3ME2xOlYvQDR3IN88US=> MVrTRW5ITVJ?
MDA-MB-231 M1fWcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnxRYNKSzVyPUG3O{42ODNizszN NWnEN|ltW0GQR1XS
no-10 NV\rPVJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHPTWM2OD1zN{iuNVM1KM7:TR?= MVTTRW5ITVJ?
MZ7-mel MmTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIr4WWlKSzVyPUG3PE41PjdizszN NXL0e|RxW0GQR1XS
NCI-H82 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;vOldKSzVyPUG4NE4yPjVizszN MlLLV2FPT0WU
CAL-72 M{TEPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4f6ZWlEPTB;MUi1MlA2PCEQvF2= NFPwWXVUSU6JRWK=
NCI-SNU-5 M3XMSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLjfZYzUUN3ME2xPFYvQDRizszN M3i3UnNCVkeHUh?=
OVCAR-4 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWm3NVl7UUN3ME2xPFgvOzN|IN88US=> MmHJV2FPT0WU
SCC-9 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIX3NYdKSzVyPUG5NUDPxE1? NGK5[oNUSU6JRWK=
KYSE-150 MnnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjaOpBDUUN3ME2xPVEvQDh6IN88US=> NFzzPVBUSU6JRWK=
HT-29 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTJyMT6yNVIh|ryP NHP1c21USU6JRWK=
COLO-678 Mm\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;sTWM2OD1{MEGuOFUh|ryP MknwV2FPT0WU
NCI-H650 M1rq[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTJyMj6xNFMh|ryP MmGwV2FPT0WU
HuCCT1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TKb2lEPTB;MkC0MlIxQCEQvF2= M4XWbHNCVkeHUh?=
SW1116 NEfLTWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jFcmlEPTB;MkC3MlA4PyEQvF2= NGTab3FUSU6JRWK=
DBTRG-05MG M1P5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DvfWlEPTB;MkC3MlkxQSEQvF2= NHzCN5hUSU6JRWK=
SW982 MoTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\QU3lxUUN3ME2yNFcvQTR6IN88US=> NGP4VFZUSU6JRWK=
RCM-1 NV;CcpBMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mle0TWM2OD1{MUSuO|YzKM7:TR?= Mlv5V2FPT0WU
COLO-320-HSR NU\kSZRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPpN4lKSzVyPUKxOk4yOjVizszN M2D5NXNCVkeHUh?=
KNS-42 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoH0TWM2OD1{MU[uOVc1KM7:TR?= MYrTRW5ITVJ?
C2BBe1 NVvYPZM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIKwbW9KSzVyPUKzNU46ODVizszN MmnwV2FPT0WU
CCRF-CEM MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHyNoxKSzVyPUK0N{44QTVizszN NUjKfXhqW0GQR1XS
SH-4 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPsTWM2OD1{NE[uNFkh|ryP M4C5NXNCVkeHUh?=
LS-1034 NIHpXoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2f3VWlEPTB;MkS2MlI3PiEQvF2= NGO2d2VUSU6JRWK=
NCI-H2347 MnizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvCOJRFUUN3ME2yOFcvPzF|IN88US=> NFqyVmNUSU6JRWK=
RPMI-8866 NVrmVm94T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXrfW1KSzVyPUK0PU4zPyEQvF2= MmfTV2FPT0WU
GAK M2j3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjjNHNKSzVyPUK1N{4xODJizszN M1GyVnNCVkeHUh?=
NB6 M3G3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTJ5MD6xJO69VQ>? MmfEV2FPT0WU
COLO-680N NV;MU|NvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTJ5Mj61Nlch|ryP Mki4V2FPT0WU
RERF-LC-MS MnrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml36TWM2OD1{N{[uNFA4KM7:TR?= M3zI[XNCVkeHUh?=
TGBC11TKB NU\kWJRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\lOGJKSzVyPUK3PE4yPzhizszN MYLTRW5ITVJ?
C8166 MmPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfjemtKSzVyPUK3PE42ODZizszN M1v5fnNCVkeHUh?=
HDLM-2 NEi3eHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;PcHJKSzVyPUK5OE41ODlizszN NHrQT3pUSU6JRWK=
IGR-1 NE\iWVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvQN3lNUUN3ME2yPVUvPjV7IN88US=> M{LBTXNCVkeHUh?=
FADU MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojqTWM2OD1{OUeuOVEh|ryP NHzZUGRUSU6JRWK=
L-428 NW\MSGVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVG4RXdFUUN3ME2yPVcvPjF4IN88US=> NE\GUYZUSU6JRWK=
LU-65 Mk\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\Ze2lEPTB;M{C0MlMzKM7:TR?= NXfN[|k{W0GQR1XS
HEL MnWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fGbWlEPTB;M{C5Mlk5OyEQvF2= NIXuZZRUSU6JRWK=
NCI-H810 NIrRNnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTNzMD61O{DPxE1? M3vmTHNCVkeHUh?=
C3A NFHITYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XNT2lEPTB;M{GxMlgxOiEQvF2= MWXTRW5ITVJ?
NCI-H630 MlLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDGN2pKSzVyPUOzNk4zQTRizszN NVjDSItvW0GQR1XS
KP-N-YN M{\DNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;KWmlEPTB;M{SxMlEzOyEQvF2= MnfiV2FPT0WU
MOLT-13 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjpPFZKSzVyPUO0Nk4{OjZizszN NInEXItUSU6JRWK=
NCI-H1993 NIm3XG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\xVolRUUN3ME2zOFIvOzZ3IN88US=> M4jGVXNCVkeHUh?=
BE-13 M{X3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTN2ND6xOlch|ryP NE\3b3lUSU6JRWK=
IST-SL1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\VfZllUUN3ME2zOFcvPDBzIN88US=> M1O4TXNCVkeHUh?=
TE-9 M2TxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XrdGlEPTB;M{[zMlU5QSEQvF2= MnfWV2FPT0WU
LU-135 M4D3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vLVWlEPTB;M{[3MlA{PSEQvF2= NUK0OndyW0GQR1XS
T84 NXTnSXBUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILBUnpKSzVyPUO3OE44OTJizszN NU\ZVoRUW0GQR1XS
K-562 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTN6Mz6zOkDPxE1? MnPHV2FPT0WU
SBC-5 M{HNdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTN6Nj65PFUh|ryP M4\aWXNCVkeHUh?=
NB17 NXSweGlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTN7Mj61PVYh|ryP Ml7vV2FPT0WU
NCI-H2052 Ml\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHrVYRKSzVyPUO5PE41PzJizszN NXvVZZd4W0GQR1XS
HCC38 NFLvOYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jmXmlEPTB;NECxMlU6OyEQvF2= NUG1fHZpW0GQR1XS
NCI-H69 M2XkbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUj4OIN6UUN3ME20OFEvODh|IN88US=> NF25NGhUSU6JRWK=

... Click to View More Cell Line Experimental Data
In vivo MK-2206 shows 60% TGI and inhibits more than 70 % of phospho-Akt1/2 (T308 and S473) in A2780 ovarian cancer xenografts at a dose of 240 mg/kg. [1] MK-2206 exhibits significant antitumor activity in NCI-H292 xenograft in combination with erlotinib or lapatinib. [2]

Protocol

Kinase Assay:

[4]
+ Expand

Akt kinases assay:

Akt kinases are assayed by a GSK-derived biotinylated peptide substrate. The extent of peptide phosphorylation is determined by Homogeneous Time Resolved Fluorescence (HTRF) using a lanthanide chelate (Lance)-coupled monoclonal antibody specific for the phosphopeptide in combination with a streptavidin-linked allophycocyanin (SA-APC) fluorophore which will bind to the biotin moiety on the peptide. When the Lance and APC are in proximity, a non-radiative energy transfer takes place from the Lance to the APC, followed by emission of light from APC at 655 nm. Working Solution: 100X protease inhibitor cocktail (PIC): 1mg/mL benzamidine, 0.5 mg/mL pepstatin, 0.5 mg/mL leupeptin, 0.5 mg/mL aprotinin; 10X assay buffer: 500 mM HEPES, pH7.5, 1% PEG, 16.6 mM EDTA, 1 mM EGTA, 1% BSA, 20 mM 9-glycerol phosphate; Quench buffer 50 mM HEPES pH 7.3, 16.6 mM EDTA, 0.1% BSA, 0.1% Triton X-100, 0.17 nM labeled monoclonal antibody, 0.0067 mg/mL SA-APC; ATP/MgCl2 working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, active Akt; Peptide working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, 2 TM GSK biotinylated peptide. The reaction is assembled by adding 16 µL of ATP/MgCl2 working solution to the appropriate wells. MK-2206 or vehicle (1.0 µL) is added followed by 10 µL of peptide working solution. The reaction is started by adding 13 μL of the enzyme working solution and mixing. The reaction is allowed to proceed for 50 min and then stopped by the addition of 60 µL HTRF quench buffer. The stopped reactions are incubated at room temperature for at least 30 min and then read in the instrument.
Cell Research:

[2]
+ Expand
  • Cell lines: A431, HCC827, NCI-H292, NCI-H358, NCI-H23, NCI-H1299, Calu-6 and NCI-H460 cells
  • Concentrations: 0, 0.3, 1 and 3 μM
  • Incubation Time: 72 or 96 hours
  • Method:

    MK-2206 is dissolved in DMSO as a stock solution and diluted by culture media before use. Cells are seeded at a density of 2-3 × 103 in 96-well plates and incubated for 24 hours. Then MK-2206 (0, 0.3, 1 and 3 μM) is added to the cells. Cell proliferation is determined after 72 or 96 hours.


    (Only for Reference)
Animal Research:

[2]
+ Expand
  • Animal Models: SK-OV-3, NCI-H292, HCC70, PC-3, and NCI-H460 models in male CD1-nude mice
  • Formulation: Formulated in 30% Captisol
  • Dosages: 120 mg/kg
  • Administration: Orally administered
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 14 mg/mL (29.14 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
15% Captisol
For best results, use promptly after mixing. 		17 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 480.39
Formula

C25H21N5O.2HCl
CAS No. 1032350-13-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01802320 Active not recruiting Colon Mucinous Adenocarcinoma|Colon Signet Ring Cell Adenocarcinoma|Rectal Mucinous Adenocarcinoma|Rectal Signet Ring Cell Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage IIIA Colon Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer National Cancer Institute (NCI) March 2013 Phase 2
NCT01859182 Withdrawn Adenocarcinoma of the Gallbladder|Adenocarcinoma With Squamous Metaplasia of the Gallbladder|Adult Primary Cholangiocellular Carcinoma|Advanced Adult Primary Liver Cancer|Cholangiocarcinoma of the Extrahepatic Bile Duct|Localized Unresectable Adult Primary Liver Cancer|Metastatic Extrahepatic Bile Duct Cancer|Recurrent Adult Primary Liver Cancer|Recurrent Extrahepatic Bile Duct Cancer|Stage II Gallbladder Cancer|Stage IIIA Gallbladder Cancer|Stage IIIB Gallbladder Cancer|Stage IVA Gallbladder Cancer|Stage IVB Gallbladder Cancer|Unresectable Extrahepatic Bile Duct Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01783171 Completed Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage III Pancreatic Cancer AJCC v6 and v7|Stage IV Pancreatic Cancer AJCC v6 and v7|Unresectable Pancreatic Carcinoma National Cancer Institute (NCI) January 15 2013 Phase 1
NCT01776008 Terminated Estrogen Receptor Positive|HER2/Neu Negative|Recurrent Breast Carcinoma|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01705340 Terminated Adenocarcinoma of the Gastroesophageal Junction|HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Recurrent Esophageal Cancer|Recurrent Gastric Cancer|Stage IIIC Breast Cancer|Stage IIIC Esophageal Cancer|Stage IIIC Gastric Cancer|Stage IV Breast Cancer|Stage IV Esophageal Cancer|Stage IV Gastric Cancer National Cancer Institute (NCI) September 2012 Phase 1
NCT01658943 Completed Pancreatic Acinar Cell Carcinoma|Pancreatic Ductal Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage IV Pancreatic Cancer National Cancer Institute (NCI) August 2012 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is your recommendation for preparing the solution and how would you deliver it to the mice (i.p. or gavage)?

  • Answer:

    You can resuspend MK-2206 in 15% Captisol at up to 17mg/ml. It's a suspension and is for oral gavage use only.

  • Question 2:

    I would want to know if MK-2206 could cross the blood brain barrier?

  • Answer:

    MK-2206 can cross BBB based on the following reference: https://clinicaltrials.gov/ct2/show/NCT01249105.

selleck catalog

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

  • Selective Akt Inhibitor

    CCT128930 : AKT2-selective, IC50=6 nM.

  • Most Potent Akt Inhibitor

    AZD5363 : Akt1, IC50=3 nM; Akt2, IC50=8 nM; Akt3, IC50=8 nM.

  • Akt Inhibitor in Clinical Trial

    Perifosine (KRX-0401) : Phase III fro relapsed and refractory multiple myeloma.

  • Newest Akt Inhibitor

    AZD5363 : Potent inhibitor of all isoforms of Akt (Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM, similar to P70S6K/PKA and lower activity towards ROCK1/2.

Related Akt Products4

  • Afuresertib (GSK2110183) New

    Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

  • AT13148 New

    AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.

  • SC79 New

    SC79 is a brain-penetrable Akt phosphorylation activator and an inhibitor of Akt-PH domain translocation.

  • Capivasertib (AZD5363)

    AZD5363 potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM in cell-free assays, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 2.

    Features:Moderate preclinical tolerability, and PD characteristics of an AKT inhibitor. Distinct profile from other AKT inhibitors in clinical development.

  • Ipatasertib (GDC-0068)

    Ipatasertib (GDC-0068) is a highly selective pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 5 nM/18 nM/8 nM in cell-free assays, 620-fold selectivity over PKA. Phase 2.

  • GSK690693

    GSK690693 is a pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 2 nM/13 nM/9 nM in cell-free assays, also sensitive to the AGC kinase family: PKA, PrkX and PKC isozymes. Phase 1.

  • Perifosine (KRX-0401)

    Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

  • A-674563

    A-674563 is an Akt1 inhibitor with Ki of 11 nM in cell-free assays, modest potent to PKA and >30-fold selective for Akt1 over PKC.

    Features:Orally bioavailable compound (achieved by replacing indole of A-443654 with phenyl moiety) and somewhat less selective for Akt over PKA than A-443654.

  • Triciribine

    Triciribine is a DNA synthesis inhibitor, also inhibits Akt in PC3 cell line and HIV-1 in CEM-SS, H9, H9IIIB, U1 cells with IC50 of 130 nM and 20 nM, respectively; does not inhibit PI3K/PDK1; 5000-fold less active in cells lacking adenosine kinase. Phase 1/2.

  • Honokiol

    Honokiol is the active principle of magnolia extract that inhibits Akt-phosphorylation and promotes ERK1/2 phosphorylation. Phase 3.

Tags: buy MK-2206 2HCl | MK-2206 2HCl supplier | purchase MK-2206 2HCl | MK-2206 2HCl cost | MK-2206 2HCl manufacturer | order MK-2206 2HCl | MK-2206 2HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID